Neurocrine Biosciences | Bénéfice Avant Impôts



Pre Tax Profit Changement Date
AbbVie USD 4.81B 1.54B 2024-12
Acadia Pharmaceuticals USD 161.08M 122.28M 2024-12
Agios Pharmaceuticals USD -105399000 1.11B 2024-12
ALKERMES USD 443.75M 333.52M 2024-12
Alnylam Pharmaceuticals USD -193958000 85.3M 2024-12
Amgen USD 3.38B 111M 2024-12
Biogen USD 572.2M 118.5M 2024-12
BioMarin Pharmaceutical USD 169.64M 35.2M 2024-12
Cytokinetics USD -150020000 10.52M 2024-12
Dynavax Technologies USD 7.63M 12.19M 2024-12
Exelixis USD 184.77M 30.02M 2024-12
Gilead Sciences USD 2.96B 112M 2024-12
Halozyme Therapeutics USD 557.13M 359.8M 2024-12
Incyte USD 234.19M 172.64M 2025-03
Ionis Pharmaceuticals USD -147000000 40M 2025-03
Neurocrine Biosciences USD 162.6M 27.7M 2024-12
Pfizer USD 4.44B 2.36B 2024-12
Prothena USD -59501000 335K 2024-12
Regeneron Pharmaceuticals USD 905M 53.1M 2025-03
Repligen USD 7.94M 46.55M 2025-03
Sarepta Therapeutics USD 171.74M 137.74M 2024-12
Teva Pharmaceutical Industries USD 899M 1.22B 2024-12
Ultragenyx Pharmaceutical USD -133404000 191K 2024-12
Vertex Pharmaceuticals USD 1.32B 109.7M 2024-12



Neurocrine Biosciences Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.